» Articles » PMID: 38446680

Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2024 Mar 6
PMID 38446680
Authors
Affiliations
Soon will be listed here.
Citing Articles

Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives.

Shi X, Tang K, Zhang Q, Han Q, Quan L, Li Y Front Pharmacol. 2025; 16:1556245.

PMID: 40061961 PMC: 11885230. DOI: 10.3389/fphar.2025.1556245.


Time's up: the urgency to investigate time toxicity in patients with genitourinary malignancies.

Sentana-Lledo D, Morgans A Ther Adv Med Oncol. 2024; 16:17588359241305088.

PMID: 39664299 PMC: 11632889. DOI: 10.1177/17588359241305088.


Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma.

Zhang T, Tan A, Shah A, Iyer G, Morris V, Michaud S Oncologist. 2024; 29(12):1003-1013.

PMID: 39167703 PMC: 11630754. DOI: 10.1093/oncolo/oyae215.


A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?.

Gasperoni L, Del Bono L, Ossato A, Giunta E, Messori A, Damuzzo V Cancers (Basel). 2024; 16(13).

PMID: 39001462 PMC: 11240305. DOI: 10.3390/cancers16132400.